• EnglishEnglish
    • Deutsch Deutsch
    • Italiano Italiano
    • Français Français
    • 日本語 日本語
    • 한국어 한국어

CISEMA - China Zertifizierung, Einkauf und Qualitätssicherung

  • Services
    • NMPA Registration – Medical Devices and IVDs
    • NMPA Registration – Cosmetics
    • NMPA Registration – Health Food
    • DMF (Drug Master Filing) – Pharmaceutical Products
    • CCC (China Compulsory Certification) – Industrial and consumer goods
    • CML (China Manufacture Licence) – Pressure vessels
    • Others
      • Sourcing and Quality Control
      • Logistics and Customs Support
      • Sales Support
  • About us
    • Company Profile
    • Partners
    • Testimonials
  • Locations
  • Events
    • Trade Fairs & Conferences
    • Seminars
    • Webinars
  • News & Information
    • Regulatory News
      • Medical Devices and IVDs
      • Cosmetics
      • DMF
      • CCC
      • Pressure Vessels
    • Publications
    • Brochure
    • Online Shop
Contact
  • Home
  • News
  • News
  • NMPA Registration in China
  • Medical Device
  • Guidelines for Reporting Adverse Events

Guidelines for Reporting Adverse Events

Friday, 18 December 2020 / Published in Medical Device, News, NMPA Registration in China

Guidelines for Reporting Adverse Events

On November 27, 2020, the National Medical Products Administration (NMPA) issued (No.78 – 2020) the guideline for the standard procedure that NMPA Legal Agents shall follow when submitting risk evaluation reports after an adverse event.

In general, the medical device registrants or filing persons are responsible to verify the investigation results of the adverse event, analyse the data collected from post-market surveillance and other risk reports, arrange product inspections, prepare the analysis, evaluation, and control of risks.

According to the guidelines, the medical device registrants or filing persons are advised to investigate, analyse and evaluate the occurrence of the adverse event within a short turnaround time. The medical device registrant or filing person should be prepared to carry out a risk evaluation report if any unreasonable risks of the product are identified, which could be required by the respective MPA or self-initiated by the medical device registrant or filing person.

If the medical device registrants is requested by a government official to submit the risk evaluation report, it should always be submitted directly to the National Center for ADR (Adverse Drug Reaction) Monitoring in China. Otherwise, if the risk evaluation work is self-initiated by the medical device registrant or filing person, the report should only be submitted to the local MPA, and the local MPA should forward the report to the National Center for ADR Monitoring.

By Jacky Li. Contact Cisema if you would like to learn more.

Tagged under: Adverse Events, Medical Devices, Period Risk Evaluation Report

What you can read next

CCC “Light” for the Import of Vehicles
Chinese certification authorities published measures to support the containment of the corona virus outbreak
Webinar: MedTech pathway to China: Market opportunities and regulatory hurdles
Webinar: MedTech pathway to China: Market opportunities and regulatory hurdles

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Search

Categories

  • Fairs & Events
  • News
    • CCC
    • CEL
    • CML, SELO
    • Medical Devices Listing in Hong Kong
    • NMPA Registration in China
      • Cosmetics
      • Drug Master Filing
      • Health Food
      • Medical Device
    • RoHS
  • Publications
  • Seminars
  • Webinars

Recent Posts

  • Cisema Webinar: Greater Bay Area Initiative and China NMPA Registration for Medtech

    On April 15, 2021, Cisema will cohost a webinar...
  • Cisema to attend CMEF 2021

    Once again, Cisema will be participating in the...
  • Cisema Webinar Series: NMPA Registration of Medical Devices in China

    In the first webinar of the series, we were del...
  • New Regulatory Updates Concerning Health Food Filing

    On February 20, 2021, the SAMR (State Administr...
  • New Regulatory Controls to Support the CSAR Including Animal Testing Exemptions

    On March 4, 2021, the NMPA announced the Provis...

Archive

Cisema

With twelve locations and over ninety highly qualified employees, Cisema can offer you optimal support in China.

Services

  • Certification
  • Sourcing and Quality Control
  • Logistics and Customs Support
  • Sales Support

Dialogue

  • Contact us
  • Events
  • News & Information
  • Partners

Company

  • GTC
  • Privacy Statement
  • Legal Notice
  • About us
  • Locations
  • GET SOCIAL

© 2021 Cisema. All rights reserved.

TOP